Teresa M. Foy Net Worth

The estimated Net Worth of Teresa M. Foy is at least $5.8 Тысяча dollars as of 6 May 2024. Teresa Foy owns over 44,975 units of Nanostring Technologies Inc stock worth over $5,801 and over the last 3 years Teresa sold NSTG stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Teresa Foy NSTG stock SEC Form 4 insiders trading

Teresa has made over 4 trades of the Nanostring Technologies Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Teresa exercised 44,975 units of NSTG stock worth $4,736 on 6 May 2024.

The largest trade Teresa's ever made was exercising 44,975 units of Nanostring Technologies Inc stock on 6 May 2024 worth over $4,736. On average, Teresa trades about 9,182 units every 64 days since 2022. As of 6 May 2024 Teresa still owns at least 55,091 units of Nanostring Technologies Inc stock.

You can see the complete history of Teresa Foy stock trades at the bottom of the page.

What's Teresa Foy's mailing address?

Teresa's mailing address filed with the SEC is C/O NANOSTRING TECHNOLOGIES, INC., 530 FAIRVIEW AVENUE N, SEATTLE, WA, 98109.

Insiders trading at Nanostring Technologies Inc

Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus... и Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.

What does Nanostring Technologies Inc do?

nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali

Complete history of Teresa Foy stock trades at Nanostring Technologies Inc

Nanostring Technologies Inc executives and stock owners

Nanostring Technologies Inc executives and other stock owners filed with the SEC include:

• R. Bradley Gray,
  President, Chief Executive Officer, Director
• K. Thomas Bailey,
  Chief Financial Officer
• Joseph Beechem,
  Senior Vice President - Research and Development
• John Brown,
  Senior Vice President - Sales and Marketing
• David Ghesquiere,
  Senior Vice President - Corporate and Business Development
• R. Bradley Gray,
  CEO, Pres & Director
• K. Thomas Bailey M.B.A.,
  Chief Financial Officer
• Dr. Joseph M. Beechem,
  Chief Scientific Officer and Sr. VP of R&D
• J. Chad Brown,
  Sr. VP of Sales & Marketing
• David W. Ghesquiere,
  Sr. VP of Corp. & Bus. Devel.
• William Young,
  Independent Chairman of the Board
• Gregory Norden,
  Independent Director
• Don Kania,
  Independent Director
• Charles Waite,
  Independent Director
• Elisha Finney,
  Independent Director
• Kirk Malloy,
  Independent Director
• Robert Hershberg,
  Independent Director
• Elizabeth Schneider Ph.D.,
  Sr. Global Marketing Mang.
• Dr. Philippa Webster Ph.D.,
  Sr. Principal Scientist
• Dr. Mary Tedd Allen,
  Sr. VP of Strategic Initiatives
• Kathryn Surace-Smith,
  Sr. VP of HR & Legal Affairs and Corp. Sec.
• Douglas S. Farrell,
  VP of Investor Relations & Corp. Communications
• Mark A. Winham,
  Sr. VP of Operations
• Teresa M. Foy,
  Director
• Nicholas Galakatos,
  Director
• Lifesciences Ii, L.P.Clarus...,
  
• Wayne Burns,
  SVP, Operations & Admin
• James A Johnson,
  Chief Financial Officer
• J. Chad Brown,
  SVP, Sales & Marketing
• Mary Tedd Allen,
  SVP, Operations
• Lifesciences Ii, L.P.Clarus...,
  
• Barney Saunders,
  SVP & GM, Life Sciences
• Venture Partners Vi Lpovp V...,
  
• Fisher Jurvetson Fund Vii, ...,
  
• Finny Kuruvilla,
  Director
• Tina Susan Nova,
  Director
• Bruce J. Seeley,
  SVP & GM, Diagnostics
• J Wayne Cowens,
  Chief Medical Officer
• Jennifer Scott Fonstad,
  Director
• Bradford Crutchfield,
  Director
• Janet George,
  Director
• Dana E. Rollison,
  Director
• John D. Gerace,
  Chief Commercial Officer
• Jonathan Todd Garland,
  Chief Commercial Officer